LBL-024 not checked
FollowEvery change as it happens, and a Monday email
Trials
11 active
11 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Advanced Solid Tumour (4 trials), Advanced Extrapulmonary Neuroendocrine Carcinoma, Advanced Neuroendocrine Carcinoma, Advanced Solid Tumor, Advanced Melanoma, Ovarian Cancer, Triple Negative Breast Cancer, Metastatic Colorectal Carcinoma
- Main trialPhase 3
- “This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of advanced EP-NEC patients.”In the company’s words, NCT07720193 on ClinicalTrials.gov
Other drugs for Advanced Solid Tumour
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up11
- 24 DecPhase 2 trial completes · ClinicalTrials.gov
- 28 DecPhase 1/2 trial completes · ClinicalTrials.gov
- DecPhase 1/2 trial completes · ClinicalTrials.gov
- 30 Oct 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 25 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 26 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 May 2028Phase 2 trial completes · ClinicalTrials.gov
- 26 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
- 4 Sep 2030Phase 1/2 trial completes · ClinicalTrials.gov
- 22 Dec 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 22 Dec 2030 | A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC | |
| Phase 2Recruiting | 24 Dec 2026 | A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] | |
| Phase 2Recruiting | 26 Dec 2027 | A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)] | |
| Phase 2Recruiting | 30 May 2028 | A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04] | |
| Phase 2Recruiting | 26 Dec 2028 | A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] | |
| Phase 1/2Recruiting | 28 Dec 2026 | A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma | |
| Phase 1/2Recruiting | Dec 2026 | A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors | |
| Phase 1/2Recruiting | 30 Oct 2027 | A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma. | |
| Phase 1/2Recruiting | 25 Dec 2027 | A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer | |
| Phase 1/2Recruiting | 31 Dec 2027 | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | |
| Phase 1/2Recruiting | 4 Sep 2030 | A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026